Phytoendocrinology, a state-of-the-art review of hormonally active plants and their novel endocrine applications

Read full text Summarise with VIRAT
Authors: Thomas Iff
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Abstract Plants with hormonally active properties exert their effects through a diverse set of biochemical pathways, including direct steroid receptor modulation, enzyme inhibition, and neuroendocrine signaling (Bhagwat & Haytowitz, 2015; Patisaul & Jefferson, 2010). This preprint proposes a unifying framework categorizing phytochemical endocrine activity into six primary mechanisms: phytoestrogenic activity, 5α-reductase inhibition, aromatase inhibition, luteinizing hormone (LH) stimulation, prolactin modulation, and dopaminergic regulation. Building on this framework, three novel observations are presented: (1) monoamine oxidase B (MAO-B) inhibition as an endocrinologically relevant mechanism via modulation of dopaminergic tone (Youdim & Bakhle, 2006); (2) the identification of certain botanicals as dual anti-estrogenic and anti-prolactinergic agents with downstream antiandrogenic reversal potential; and (3) the role of cortisol reduction and TRPV1 agonism as key drivers of LH upregulation (Wang et al., 2014; Herman et al., 2016). Together, these findings suggest a broader systems-level model of plant-derived endocrine modulation integrating central neurotransmitter dynamics with peripheral steroidogenesis. 1. Introduction Hormonally active plants have long been recognized in traditional medicine and increasingly studied in modern pharmacology (Panossian & Wikman, 2010). Most research has focused on isolated mechanisms—such as phytoestrogen binding or enzyme inhibition—without integrating these into a cohesive systems-level model. However, endocrine regulation is inherently multi-layered, involving feedback between the hypothalamic–pituitary–gonadal (HPG) axis, neurotransmitter systems, and peripheral metabolic enzymes (Plant, 2015). 2. Core Mechanistic Categories of Phytochemical Endocrine Activity 2.1 Phytoestrogens (+E)Phytoestrogens are plant-derived compounds that bind to estrogen receptors (ERα and ERβ), exerting agonistic or partial agonistic effects (Patisaul & Jefferson, 2010; Kuiper et al., 1998). Depending on context, they may produce net estrogenic or anti-estrogenic outcomes due to receptor competition and tissue selectivity. 2.2 5α-Reductase Inhibitors (−DHT)These compounds inhibit the conversion of testosterone to dihydrotestosterone (DHT), reducing androgenic signaling in tissues sensitive to DHT (Andersson & Russell, 1990; Habib et al., 2005). 2.3 Aromatase Inhibitors (−E)Aromatase inhibitors reduce the conversion of androgens to estrogens, thereby shifting the androgen–estrogen balance toward a more androgenic state (Simpson et al., 2002). 2.4 LH-Stimulating Compounds (+LH)Certain phytochemicals enhance luteinizing hormone secretion, either through hypothalamic stimulation (GnRH release) or indirect modulation of upstream regulators such as cortisol and neurotransmitters (Plant, 2015; Ramaswamy & Weinbauer, 2014). 2.5 Prolactinergic Compounds (+PRL)These increase prolactin levels, typically via dopamine antagonism or suppression, and may suppress gonadal function through inhibition of GnRH (Freeman et al., 2000). 2.6 Dopaminergic Compounds (−PRL)Dopamine agonists or enhancers reduce prolactin secretion by activating D2 receptors in the pituitary, thereby relieving prolactin-mediated suppression of the HPG axis (Ben-Jonathan & Hnasko, 2001). 3. Novel Mechanistic Insights 3.1 MAO-B Inhibition as an Endocrine Modulator Monoamine oxidase B (MAO-B) plays a key role in dopamine metabolism. Inhibition of MAO-B increases synaptic and postsynaptic dopamine availability (Youdim & Bakhle, 2006). Elevated dopaminergic tone leads to: Suppression of prolactin secretion via D2 receptor activation (Ben-Jonathan & Hnasko, 2001) Disinhibition of GnRH release through reduced prolactin signaling (Freeman et al., 2000) Secondary increases in LH and downstream androgen production (Plant, 2015) Thus, MAO-B inhibition should be considered an indirect but significant endocrine mechanism. 3.2 Dual Anti-Estrogenic and Anti-Prolactinergic Activity as an Antiandrogenic Reversal Strategy Certain botanicals appear to exert both anti-estrogenic (e.g., aromatase inhibition or ER antagonism) and anti-prolactinergic effects simultaneously (Jarry et al., 2003). This combination produces a synergistic endocrine shift: Reduced estrogenic negative feedback Lower prolactin-mediated suppression Enhanced LH secretion Increased androgen production 3.3 Cortisol Reduction and TRPV1 Agonism as Drivers of LH Secretion Cortisol ReductionChronic elevation of cortisol suppresses GnRH and LH secretion (Herman et al., 2016). Adaptogenic plants may normalize HPA axis activity and relieve this suppression (Panossian & Wikman, 2010). TRPV1 AgonismTransient receptor potential vanilloid 1 (TRPV1) activation has emerging relevance in neuroendocrine regulation. TRPV1 agonists may: Stimulate hypothalamic activity Enhance GnRH neuron firing Increase catecholamine release (Wang et al., 2014) Elevate endogenous opioid tone (Starowicz et al., 2007; Zubrzycka & Janecka, 2000) 4. Integrated Model of Phytochemical Endocrine Modulation The proposed framework emphasizes that plant endocrine activity is not limited to direct receptor binding or enzyme inhibition. Instead, it operates across three interconnected layers: Peripheral steroid metabolism, aromatase, 5α-reductase (Simpson et al., 2002) Receptor-level modulation, estrogenic and dopaminergic signaling (Patisaul & Jefferson, 2010) Central neuroendocrine control, GnRH, LH, prolactin, cortisol (Plant, 2015) Mechanisms such as MAO-B inhibition and TRPV1 activation highlight the importance of central nervous system pathways in mediating systemic hormonal outcomes. 5. Implications and Future Directions This framework suggests several directions for further research: Quantitative assessment of MAO-B–mediated endocrine effects Identification of plant compounds with dual anti-estrogenic and dopaminergic activity Exploration of TRPV1 agonists in reproductive endocrinology Systems biology modeling of phytochemical interactions within the HPG and HPA axes Understanding these mechanisms may improve the development of plant-based therapeutics for hormonal imbalance, hypogonadism, and prolactin-related disorders. 6. Conclusion Hormonally active plants exert their effects through a complex interplay of enzymatic, receptor-mediated, and neuroendocrine mechanisms. Expanding the framework to include monoaminergic modulation, cortisol dynamics, and TRPV1 signaling provides a more comprehensive understanding of phytochemical endocrinology. These insights support a shift from reductionist models toward integrated, systems-level approaches in the study of plant-derived endocrine modulators. References Andersson, S., & Russell, D. W. (1990). Structural and biochemical properties of cloned and expressed human and rat steroid 5α-reductases. PNAS, 87(10), 3640–3644. Ben-Jonathan, N., & Hnasko, R. (2001). Dopamine as a prolactin inhibitor. Endocrine Reviews, 22(6), 724–763. Bhagwat, S., & Haytowitz, D. B. (2015). USDA database for flavonoid content of selected foods. Freeman, M. E., et al. (2000). Prolactin: structure, function, and regulation. Physiological Reviews, 80(4), 1523–1631. Habib, F. K., et al. (2005). Serenoa repens for benign prostatic hyperplasia. Drugs & Aging, 22(5), 371–386. Herman, J. P., et al. (2016). Regulation of the HPA axis. Comprehensive Physiology, 6(2), 603–621. Jarry, H., et al. (2003). Agnus castus extracts inhibit prolactin secretion. Experimental and Clinical Endocrinology & Diabetes, 111(01), 44–48. Kuiper, G. G. J. M., et al. (1998). Interaction of estrogenic chemicals with estrogen receptor β. Endocrinology, 139(10), 4252–4263. Panossian, A., & Wikman, G. (2010). Effects of adaptogens on CNS and HPA axis. Pharmaceuticals, 3(1), 188–224. Patisaul, H. B., & Jefferson, W. (2010). Phytoestrogens and endocrine disruption. Toxicology and Applied Pharmacology, 250(1), 1–9. Plant, T. M. (2015). Neuroendocrine control of GnRH secretion. Endocrine Reviews, 36(5), 632–668. Ramaswamy, S., & Weinbauer, G. F. (2014). Endocrine control of spermatogenesis. Physiological Reviews, 94(4), 1155–1244. Simpson, E. R., et al. (2002). Aromatase and estrogen biosynthesis. Endocrine Reviews, 23(3), 275–306. Wang, S., et al. (2014). TRPV1 channels in the central nervous system. Progress in Neurobiology, 113, 1–24.Starowicz, K., Nigam, S., & Di Marzo, V. (2007). Biochemistry and pharmacology of endovanilloids. Pharmacology & Therapeutics, 114(1), 13–33.Zubrzycka, M., & Janecka, A. (2000). Substance P and opioid peptides in pain modulation. Polish Journal of Pharmacology, 52(6), 483–494. Youdim, M. B. H., & Bakhle, Y. S. (2006). Monoamine oxidase: isoforms and inhibitors. British Journal of Pharmacology, 147(S1), S287–S296.

Fields of Study & Subjects

Phytoestrogen effects and research Estrogen and related hormone effects Effects and risks of endocrine disrupting chemicals

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
26 March 2026
Language
EN
Document type
Preprint